Chugai's diagnostics sales rise 22% in new fiscal year
This article was originally published in Clinica
Japanese pharmaceutical company Chugai has reported diagnostics sales of ¥,600 million ($103 million) for the 12 months to March 1996. This represents a 22% increase compared with the 12 months to December 1994, the only comparable period after a change of year-end to March from December. In its annual report Chugai attributes the strong rise in diagnostics sales to robust demand for DNA probes.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.